Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|June 10, 2010

Teva Tests Biosimilar Version of Roche's Rituxan

Teva Pharmaceutical Industries (Tikva, Israel) is developing a generic version of Roche's (Basel, Switzerland) blockbuster antibody drug Rituxan, in what may possibly be the first US generic version of a monoclonal antibody.

Teva Pharmaceutical Industries (Tikva, Israel) is developing a generic version of Roche's (Basel, Switzerland) blockbuster antibody drug Rituxan, in what may possibly be the first US generic version of a monoclonal antibody.

Teva is recruiting 60 patients in Germany and Hungary for a clinical trial comparing Roche's original product with its copy, known as TL011, in patients with rheumatoid arthritis. The study is due for completion in August 2011, according to a post on clinicaltrials.gov.

Teva's partner Lonza (Basel, Switzerland) was also involved in the trial and the drug is expected to be launched in the second half of 2014, assuming positive results in development and approval from regulators.

Rituxan, also known as MabThera, is marketed for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia. It is one of the older antibody drugs that generics companies are now eyeing as a major sales opportunity.

With the global market for branded biologic drugs worth more than $80 billion a year and roughly $50 billion of that business set to lose patent protection by 2015 or 2016, biosimilars like Rituxan are an enticing prospect.


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.